Rapid generation of coronaviral immunity using recombinant peptide modified nanodiamonds
Rostyslav Bilyy
(1)
,
Quentin Pagneux
(2)
,
Nathan François
(3)
,
Galyna Bila
(1)
,
Roman Grytsko
(1)
,
Yuri Lebedin
(4)
,
Alexandre Barras
(2, 5)
,
Jean Dubuisson
(3)
,
Sandrine Belouzard
(3)
,
Karin Séron
(3)
,
Rabah Boukherroub
(2, 5)
,
Sabine Szunerits
(2, 5)
1
Danylo Halytsky Lviv National Medical University [Lviv, Ukraine]
2 IEMN - Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520
3 CIIL - Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204
4 XEMA-MEDICA Co
5 NBI - IEMN - NanoBioInterfaces - IEMN
2 IEMN - Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520
3 CIIL - Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204
4 XEMA-MEDICA Co
5 NBI - IEMN - NanoBioInterfaces - IEMN
Rostyslav Bilyy
- Fonction : Auteur
- PersonId : 774468
- ORCID : 0000-0002-2344-1349
Alexandre Barras
- Fonction : Auteur
- PersonId : 745941
- IdHAL : alexandre-barras
- ORCID : 0000-0003-2821-7079
- IdRef : 139076123
Jean Dubuisson
- Fonction : Auteur
- PersonId : 174819
- IdHAL : jean-dubuisson
- ORCID : 0000-0003-1626-7693
- IdRef : 109475526
Sandrine Belouzard
- Fonction : Auteur
- PersonId : 757184
- ORCID : 0000-0002-9972-4054
- IdRef : 094280266
Karin Séron
- Fonction : Auteur
- PersonId : 736058
- IdHAL : karin-seron
- ORCID : 0000-0002-9667-133X
- IdRef : 11223125X
Rabah Boukherroub
- Fonction : Auteur
- PersonId : 177969
- IdHAL : rabah-boukherroub
- ORCID : 0000-0002-9795-9888
- IdRef : 139279474
Sabine Szunerits
- Fonction : Auteur
- PersonId : 21321
- IdHAL : sabine-szunerits
- ORCID : 0000-0002-1567-4943
- IdRef : 097506362
Résumé
Vaccination remains one of the most effective tools to prevent infectious diseases. To ensure that the best possible antigenic components are chosen to stimulate a cognitive immune response, boosting antigen presentation using adjuvants is common practice. Nanodiamond-based adjuvants are proposed here as a rapid and versatile platform for antigen conjugation, utilizing peptides common to different pathogenic strains and making this strategy a good candidate for a “ready-to-use” vaccine. Initiation of an inflammatory reaction with a resulting immune response is based on the ability of living organisms to entrap nanostructures such as nanodiamonds with neutrophil extracellular traps (NETs) formation. In this work, coronavirus peptide homological for MERS-CoV, fusion inhibitor, was conjugated to nanodiamonds and used to induce neutrophilic-driven self-limiting inflammation. The resulting adjuvant was safe and did not induce any tissue damage at the site of injection. Mice immunization resulted in IgG titers of ¼,000 within 28 days. Immunization of rabbits resulted in the formation of a high level of antibodies persistently present for up to 120 days after the first immunization (animal lifespan ~3 years). The peptide used for immunization proved to be reactive with sera of convalescent COVID patients, demonstrating the possibility of developing pancoronaviral vaccine candidates.
Domaines
Sciences de l'ingénieur [physics]Format du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Rapid generation of coronaviral immunity using recombinant peptide modified nanodiamonds
|
Résumé |
en
Vaccination remains one of the most effective tools to prevent infectious diseases. To ensure that the best possible antigenic components are chosen to stimulate a cognitive immune response, boosting antigen presentation using adjuvants is common practice. Nanodiamond-based adjuvants are proposed here as a rapid and versatile platform for antigen conjugation, utilizing peptides common to different pathogenic strains and making this strategy a good candidate for a “ready-to-use” vaccine. Initiation of an inflammatory reaction with a resulting immune response is based on the ability of living organisms to entrap nanostructures such as nanodiamonds with neutrophil extracellular traps (NETs) formation. In this work, coronavirus peptide homological for MERS-CoV, fusion inhibitor, was conjugated to nanodiamonds and used to induce neutrophilic-driven self-limiting inflammation. The resulting adjuvant was safe and did not induce any tissue damage at the site of injection. Mice immunization resulted in IgG titers of ¼,000 within 28 days. Immunization of rabbits resulted in the formation of a high level of antibodies persistently present for up to 120 days after the first immunization (animal lifespan ~3 years). The peptide used for immunization proved to be reactive with sera of convalescent COVID patients, demonstrating the possibility of developing pancoronaviral vaccine candidates.
|
Auteur(s) |
Rostyslav Bilyy
1
, Quentin Pagneux
2
, Nathan François
3
, Galyna Bila
1
, Roman Grytsko
1
, Yuri Lebedin
4
, Alexandre Barras
2, 5
, Jean Dubuisson
3
, Sandrine Belouzard
3
, Karin Séron
3
, Rabah Boukherroub
2, 5
, Sabine Szunerits
2, 5
1
Danylo Halytsky Lviv National Medical University [Lviv, Ukraine]
( 481240 )
- Pekarska Str., 69, Lviv, 79010, Ukraine
- Ukraine
2
IEMN -
Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520
( 1066983 )
- [Univ. Lille, CNRS, Centrale Lille Institut, Junia, Univ. Polytechnique Hauts-de-France] ––
Laboratoire Central – Cité Scientifique – Avenue Poincaré – CS 60069 – 59652 VILLENEUVE D’ASCQ CEDEX
- France
3
CIIL -
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204
( 106189 )
- 1 Rue du Professeur Calmette - Lille Cedex - 59019 - BP 245
- France
4
XEMA-MEDICA Co
( 46655 )
- Moscow
- Russie
5
NBI - IEMN -
NanoBioInterfaces - IEMN
( 1067477 )
- Groupe NBI - CCHB IRCICA - 50 Avenue Halley - 59650 Villeneuve d'Ascq
- France
|
Nom de la revue |
|
Licence |
Paternité
|
Langue du document |
Anglais
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Date de publication |
2021-07-08
|
Date de publication électronique |
2021-07-08
|
Volume |
10
|
Numéro |
7
|
Page/Identifiant |
861
|
Référence interne |
|
Projet(s) ANR |
|
Projet(s) Européen(s) |
|
Domaine(s) |
|
Financement |
|
DOI | 10.3390/pathogens10070861 |
PubMed Central | PMC8308543 |
UT key WOS | 000677342200001 |
Origine :
Fichiers éditeurs autorisés sur une archive ouverte
Loading...